Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00047866
Other study ID # 030013
Secondary ID 03-AA-0013
Status Completed
Phase N/A
First received October 22, 2002
Last updated June 30, 2017
Start date October 12, 2002
Est. completion date June 25, 2010

Study information

Verified date June 25, 2010
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study seeks more information about the biology of substance dependency by exploring the brain areas involved in feeling positive and negative emotions. Specifically, it will determine whether a brain chemical called dopamine affects activity in certain brain regions during performance of a game that involves winning and losing money. Brain activity will be examined using magnetic resonance imaging (MRI), a test that uses a magnetic field and radio waves to produce images of brain structure and function.

Young to middle-aged healthy adults may participate in this study. Candidates will be screened with a medical history, physical examination, electrocardiogram (EKG), psychiatric interview, and blood and urine tests. Participants will be assigned to one of the two study procedures, as follows:

Tyrosine/Phenylalanine

This study requires two overnight stays at the NIH Clinical Center. For each stay, subjects are admitted to the hospital the afternoon before the MRI scan. From the time of admission until after the scan, their diets are restricted to food relatively low in amino acids, prepared by NIH dietitians. The next day, participants undergo MRI scanning. For this procedure, the subject lies on a table that is moved into the scanner, a metal cylindrical machine. Earplugs are worn to muffle loud noises that occur with electrical switching of the radio frequency circuits. Imaging of brain structure takes about 10 to 15 minutes. Additional scans are then taken to measure brain activity while the subject plays simple computer games for money. These scans take about another 20 to 45 minutes. Five hours before the MRI, the subject drinks one of two beverages containing amino acids. A different beverage is given for each of the two visits: one drink lacks the essential amino acids tyrosine and phenylalanine, from which the body makes dopamine; the other contains balanced amounts of these two amino acids. Finally, subjects fill out mood-rating questionnaires before and after drinking each of the beverages.

Dextroamphetamine

This study requires two outpatient visits to the NIH Clinical Center. For one visit, participants are given an injection of 0.2 mg/kg body weight of the drug dextroamphetamine; for the other, they are given an injection of saline (salt water). After each injection, they undergo MRI scanning while playing computer games for money, as described above. They will fill out mood-rating questionnaires before and after each brain scan.


Description:

The purpose of this protocol is to advance the understanding of the behavioral neurobiology underlying substance dependency by exploring regional brain activity in response to appetitive and aversive stimuli in human subjects. In this protocol, brain activation is the dependent measure, as measured by blood oxygenation level dependent (BOLD) signal acquired during functional magnetic resonance (fMRI) imaging. Previous work in this laboratory has found that cues of anticipated monetary reward versus threat of negative reinforcement causes increased BOLD signal in the nucleus accumbens (NAcc) and other parts of the ventral striatum. This protocol is intended to extend these findings by exploring whether the recently reported BOLD activation (a hemodynamic response) in certain brain regions in response to motivational cues can be perturbed by dopaminergic pharmacological manipulations.

In a series of two, repeated-measures, within-subject experiments, we propose to temporarily alter subjects' brain monoamine neurotransmitter systems with pharmacological interventions prior to presenting the subjects with appetitive and aversive visual stimuli as well as cues signaling potential punishment and reward. In the first experiment, brain catecholamine systems will be deactivated by dietary restrictions of amino acid precursors Tyrosine (Tyr) and Phenylalanine (Phe), respectively. In the second experiment, the brain dopamine (DA) release will be transiently increased with administration of dextroamphetamine (Amph). Based on a wealth of existent findings, we predict that acutely enhancing synaptic DA by Amph will augment reward-elicited activation in the ventral striatum. Conversely, acute dietary restriction of the DA precursor Tyr, (along with Tyr precursor Phe) will blunt this activation. Since substance use disorders (SUD) such as alcoholism may result from disordered neural systems regulating approach and avoidance behavior (with respect to the substance), this experiment can yield useful knowledge relevant to SUD.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date June 25, 2010
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility - INCLUSION AND EXCLUSION CRITERIA:

Subjects are physically healthy as determined by medical evaluation at the NIAAA outpatient clinic. In particular, subjects must demonstrate no cardiovascular or blood pressure abnormalities, such as a resting blood pressure of 140/90 or greater. All values of laboratory test must be within the NIH defined normal range and all radiological and cardiac evaluations must be considered normal by the NIH radiologist or cardiologist reading the scan or record. As is usual clinical practice, in the case of minor abnormalities a lab test may be repeated to ensure the validity of the initial report.

Are between 18-65 years of age.

Have 20/20 vision or wear corrective contact lenses. Plastic glasses with pop-in lenses of different strengths are available in the NMR center for use with nearsighted subjects who do not wear contacts.

Have no ferromagnetic objects in their bodies which might be adversely affected by MRI (e.g. surgical clips; metal fragments in or near brain; eye or blood vessels; cardiac or neurological pacemaker; cochlear or eye implant - any doubt about absence of these objects will result in exclusion from this study).

Test HIV negative.

Have no indication of any organic brain syndrome.

Do not meet criteria for any present or past Axis I psychiatric disorder, including nicotine dependence. Smokers will be excluded.

Have no active homicidal or suicidal ideation, or active symptoms of post-traumatic stress disorder.

Are not currently receiving psychotropic medication or medication likely to affect brain neurotransmitter systems.

Have no indication of recent drug use as evidenced by urine drug screen and self-report.

Are not pregnant or lactating.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Holland P, Mushinski M. Costs of alcohol and drug abuse in the United States, 1992. Alcohol/Drugs COI Study Team. Stat Bull Metrop Insur Co. 1999 Oct-Dec;80(4):2-9. — View Citation

Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci. 2000;909:170-85. Review. — View Citation

Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997 Apr 24;386(6627):830-3. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT02564341 - Targeting Effective Analgesia in Clinics for HIV - Intervention N/A
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT00593463 - Drug Discrimination in Methadone-Maintained Humans Study 1 Phase 1
Completed NCT03678051 - CBT4CBT for Women in Residential Treatment for Substance Use Disorders N/A
Recruiting NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification Phase 2
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A
Completed NCT03694327 - Innovative Digital Therapeutic for Smoking Cessation N/A
Completed NCT01449981 - Development and Testing of Adolescent Twelve-Step Facilitation N/A
Completed NCT00183118 - Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment) Phase 1/Phase 2
Recruiting NCT03333460 - Transcranial Magnetic Stimulation for Cocaine Addiction N/A
Completed NCT02124980 - Automated Recovery Line for Medication Assisted Treatment N/A
Terminated NCT00975416 - Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Phase 4
Completed NCT00265512 - LINK: Aftercare Monitoring Project N/A
Completed NCT00706901 - Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans N/A
Completed NCT02656745 - Clinical Trial of Smoking Cessation Mobile Phone Program N/A
Withdrawn NCT00675532 - Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol). N/A
Active, not recruiting NCT03539575 - CB1R in Synthetic Psychoactive Cannabinoids N/A
Completed NCT01246401 - Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations Phase 1/Phase 2
Completed NCT01096550 - Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans N/A
Completed NCT00605033 - A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Phase 4